BioSpace News Archive

As we head into the winter months, Canadians are doing everything they can protect themselves from the risk of getting sick. It turns out that if you DO find yourself in hospital, you may face a different set of risks – the risk of receiving the wrong medication based on your genetics. Now, a new test can help.

Intrivo Diagnostics , a Los Angeles-based diagnostic testing provider for high-quality testing solutions for COVID-19, today announced that it will begin national distribution and commercialization of diagnostic testing products developed by New Jersey-based testing manufacturer, Access Bio, Inc . through McKesson Medical-Surgical . McKesson joins Concordance Healthcare Solutions and NDC, Inc. as key national partners within

BIOLASE and BMW Performance Center West team together for a 12-Month promotion to give dentists a thrilling opportunity to experience the precision, control and performance of the advanced Waterlase dental laser and BMW award-winning vehicles

Asembia’s 2021 Specialty Pharmacy Summit will take place October 26 through October 29, 2021 at the Wynn Las Vegas. The date change for 2021 is due to challenges from COVID -19 which have disrupte

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis’ state-of-the-art tumor neoantigen prediction tool, SHERPA™, with mechanisms of immune evasion to better predict response to cancer therapy. NEOPS combines the tumor genomic and immune-related analytics of the Person

Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces today it has entered into a partnership with Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions

Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss, a serious and debi

Adial Pharmaceuticals, Inc. today announced it has reached the 35% enrollment target in the Company’s landmark ONWARD™ Phase 3 pivotal trial in Europe. ONWARD™ is investigating the efficacy and safety of Adial’s lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD)

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares (“Ordinary Shares”) on the standard listing segment of the Official List of the Financial Conduct Authority (“FCA”) (the “Official List”) and admission to trading on the London Stock Exc

Next Generation System Provides Efficiency-Focused Workflow Enhancements, Pathology Engine, and PENTAX Connect Compatibility